Parkinson's

People with Parkinson's urgently need new treatments. But right now, there's a huge gap in drug development. The Parkinson's Virtual Biotech exists to bridge that critical funding shortage. It takes the most promising research and partners with institutions and pharmaceutical companies worldwide to develop the findings into plausible drug treatments. Currently there are projects at the non-clinical, preclinical and early clinical development stages. With no large teams of scientists or expensive labs to run, the Parkinson's Virtual Biotech ensures that every penny of the annual £4m investment goes on what matters most: fast tracking the projects with the greatest potential to transform the lives of people with Parkinson's. No one else is doing this. It's a bold risk. But we believe it will deliver a groundbreaking new treatment by 2024. Because people with Parkinson's won't wait. Together, we'll find a cure.